Status: Not yet recruiting
KN026 Plus Chemotherapy ± KN-046 in HER2 Positive Colorectal Cancer and Biliary Carcinoma
The goal of this Interventional clinical trial is to learn about the efficacy and safety of KN026 and chemotherapy ± KN046 in HER2-positive metastatic colorectal cancer and biliary tract cancer. Participants will receive standard first-line chemotherapy (capecitabine + oxaliplatin) combined with KN026 (a HER2-targeted bispecific antibody) ± KN046 （a PD-L1/CTLA-4 targeted bispecific antibody）.
Participants needed: 80
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Peking University Cancer Hospital & InstituteUpdated: Aug 21, 2023Locations: 1
Eligibility criteria
Participants are able to comprehend the informed consent information and sign th... [+10]
Subjects with untreated active brain metastases or leptomeningeal metastases; if... [+18]